Maltose ( DrugBank: Maltose )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02680756 (ClinicalTrials.gov)	January 2016	9/2/2016	Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD	A Phase 3b, Randomized, Controlled, Multicentre Study With Oral Ferric Maltol (Feraccru) or Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anaemia in Subjects With Inflammatory Bowel Disease	Anemia, Iron-Deficiency;Inflammatory Bowel Disease;Crohn's Disease	Drug: Ferric Maltol;Drug: Ferric Carboxy Maltose	Shield Therapeutics	NULL	Completed	18 Years	N/A	All	250	Phase 3	United States;Belgium;France;Germany;Hungary;Spain

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs041190010	06/04/2018	10/04/2019	The usefulness of kestose for ulcerative colitis	The usefulness of kestose for ulcerative colitis	Ulcerative colitis	arm A Kestose(10g) every day 8 weeksar arm B Maltose(5g) every day 8 weeks	Honda Takashi	NULL	Not Recruiting	>= 20age old	<= 80age old	Both	40	N/A	Japan